IQVIA (NYSE:IQV) Price Target Lowered to $265.00 at Evercore ISI

IQVIA (NYSE:IQV) had its target price lowered by analysts at Evercore ISI from $270.00 to $265.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Evercore ISI’s target price suggests a potential upside of 17.16% from the stock’s current price.

IQV has been the topic of a number of other research reports. Morgan Stanley increased their price objective on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. UBS Group lifted their price target on shares of IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Truist Financial upped their price objective on shares of IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Finally, JPMorgan Chase & Co. upped their price target on shares of IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a report on Monday, August 5th. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $266.67.

IQVIA Stock Up 0.4 %

NYSE:IQV traded up $0.82 during mid-day trading on Tuesday, reaching $226.18. The stock had a trading volume of 273,243 shares, compared to its average volume of 1,072,410. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The stock has a market cap of $41.23 billion, a P/E ratio of 30.85, a PEG ratio of 2.18 and a beta of 1.49. The business’s 50 day moving average is $240.50 and its 200 day moving average is $232.20. IQVIA has a fifty-two week low of $167.42 and a fifty-two week high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. The business had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. IQVIA’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the firm earned $2.22 EPS. As a group, sell-side analysts predict that IQVIA will post 10.25 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Jennison Associates LLC raised its position in IQVIA by 7.3% in the 1st quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock valued at $35,636,000 after purchasing an additional 9,578 shares during the last quarter. Nomura Holdings Inc. bought a new position in IQVIA in the 4th quarter valued at $857,000. PGGM Investments increased its stake in shares of IQVIA by 55.8% in the 2nd quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after buying an additional 4,326 shares during the period. Fiduciary Alliance LLC bought a new stake in IQVIA during the 1st quarter worth about $1,864,000. Finally, SG Americas Securities LLC lifted its holdings in IQVIA by 80.1% in the first quarter. SG Americas Securities LLC now owns 45,787 shares of the medical research company’s stock valued at $11,579,000 after buying an additional 20,369 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.